IP10.C8

Immune Technologies & Medicine GmbH · Phase 2 active Small molecule

At a glance

Generic name	IP10.C8
Sponsor	Immune Technologies & Medicine GmbH
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IP10.C8 CI brief — competitive landscape report
IP10.C8 updates RSS · CI watch RSS
Immune Technologies & Medicine GmbH portfolio CI